Quidel Corporation (QDEL): Price and Financial Metrics


Quidel Corporation (QDEL): $134.10

-0.78 (-0.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

QDEL POWR Grades


  • Value is the dimension where QDEL ranks best; there it ranks ahead of 95.71% of US stocks.
  • QDEL's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • QDEL ranks lowest in Stability; there it ranks in the 3rd percentile.

QDEL Stock Summary

  • QDEL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1.22 -- higher than only 6.32% of US-listed equities with positive expected earnings growth.
  • Over the past twelve months, QDEL has reported earnings growth of 508.34%, putting it ahead of 95.35% of US stocks in our set.
  • As for revenue growth, note that QDEL's revenue has grown 180.46% over the past 12 months; that beats the revenue growth of 96.15% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Quidel Corp are EYPT, IRBT, AVGR, NTGR, and NXGN.
  • Visit QDEL's SEC page to see the company's official filings. To visit the company's web site, go to www.quidel.com.

QDEL Valuation Summary

  • QDEL's price/earnings ratio is 6; this is 83.56% lower than that of the median Healthcare stock.
  • QDEL's price/earnings ratio has moved up 24.7 over the prior 243 months.
  • Over the past 243 months, QDEL's EV/EBIT ratio has gone up 28.7.

Below are key valuation metrics over time for QDEL.

Stock Date P/S P/B P/E EV/EBIT
QDEL 2021-08-31 2.9 3.8 6.0 4.2
QDEL 2021-08-30 2.9 3.8 6.0 4.3
QDEL 2021-08-27 2.9 3.8 5.9 4.2
QDEL 2021-08-26 2.8 3.7 5.8 4.1
QDEL 2021-08-25 2.7 3.6 5.6 4.0
QDEL 2021-08-24 2.8 3.6 5.6 4.0

QDEL Growth Metrics

  • Its 5 year net cashflow from operations growth rate is now at 323.21%.
  • Its 3 year cash and equivalents growth rate is now at -62.89%.
  • Its 2 year net cashflow from operations growth rate is now at 379.46%.
Over the past 15 months, QDEL's revenue has gone up $1,275,634,000.

The table below shows QDEL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 1,837.209 917.019 899.555
2021-03-31 1,862.353 1,154.04 948.134
2020-12-31 1,661.668 629.763 810.287
2020-09-30 1,004.643 238.356 370.783
2020-06-30 655.077 181.231 154.696
2020-03-31 561.575 162.768 88.314

QDEL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • QDEL has a Quality Grade of B, ranking ahead of 85.04% of graded US stocks.
  • QDEL's asset turnover comes in at 1.046 -- ranking 22nd of 681 Pharmaceutical Products stocks.
  • SYRS, ONVO, and SESN are the stocks whose asset turnover ratios are most correlated with QDEL.

The table below shows QDEL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.046 0.813 1.894
2021-03-31 1.203 0.825 2.292
2020-12-31 1.314 0.812 2.053
2020-09-30 0.980 0.739 1.094
2020-06-30 0.705 0.663 0.537
2020-03-31 0.625 0.614 0.329

QDEL Price Target

For more insight on analysts targets of QDEL, see our QDEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $127.75 Average Broker Recommendation 1.8 (Moderate Buy)

QDEL Stock Price Chart Interactive Chart >

Price chart for QDEL

QDEL Price/Volume Stats

Current price $134.10 52-week high $288.70
Prev. close $134.88 52-week low $103.31
Day low $134.00 Volume 6,881
Day high $134.87 Avg. volume 791,777
50-day MA $135.89 Dividend yield N/A
200-day MA $142.87 Market Cap 5.58B

Quidel Corporation (QDEL) Company Bio


Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, women’s health, and gastrointestinal diseases. The company was founded in 1979 and is based in San Diego, California.


QDEL Latest News Stream


Event/Time News Detail
Loading, please wait...

QDEL Latest Social Stream


Loading social stream, please wait...

View Full QDEL Social Stream

Latest QDEL News From Around the Web

Below are the latest news stories about Quidel Corp that investors may wish to consider to help them evaluate QDEL as an investment opportunity.

Quidel to Hold Fiscal Third Quarter 2021 Financial Results Conference Call on November 4th, 2021

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal third quarter 2021 financial results after market close on Thursday, November 4, 2021. Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. E

Business Wire | October 20, 2021

Pediatric Lyme DiseaseAn Epidemic Within a Pandemic!to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21

SAN DIEGO--(BUSINESS WIRE)-- #infectiousdisease--Among the many health challenges facing children ages 0-19 is the very real threat of contracting Lyme disease.

Business Wire | October 18, 2021

DGAP-News: Quidel Corporation: Pediatric Lyme Disease-''An Epidemic Within a Pandemic!''-to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21

DGAP-News: Quidel Corporation Pediatric Lyme Disease-''An Epidemic Within a Pandemic!''-to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21 18.10.2021 / 20:56 The issuer is solely respo

FinanzNachrichten | October 18, 2021

Pediatric Lyme Disease—‘An Epidemic Within a Pandemic!’—to be Focus of Free Webinar Hosted by Quidel Corporation Oct. 21

SAN DIEGO, October 18, 2021--Among the many health challenges facing children ages 0-19 is the very real threat of contracting Lyme disease.

Yahoo | October 18, 2021

Quest Diagnostics (DGX) Base Arm Recovers, Testing Sales Grow

Quest Diagnostics (DGX) is hopeful about the fact that COVID-19 testing remains critical as employees are returning to the workplace and students to the classroom.

Yahoo | October 15, 2021

Read More 'QDEL' Stories Here

QDEL Price Returns

1-mo -8.74%
3-mo -2.26%
6-mo 20.81%
1-year -45.97%
3-year 114.97%
5-year 526.34%
YTD -25.35%
2020 139.44%
2019 53.69%
2018 12.62%
2017 102.38%
2016 1.04%

Continue Researching QDEL

Here are a few links from around the web to help you further your research on Quidel Corp's stock as an investment opportunity:

Quidel Corp (QDEL) Stock Price | Nasdaq
Quidel Corp (QDEL) Stock Quote, History and News - Yahoo Finance
Quidel Corp (QDEL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.823 seconds.